靶向RBM39-MEK5轴与硼替佐米协同抑制多发性骨髓瘤的恶性生长
本研究探讨剪接因子RBM39在多发性骨髓瘤(MM)中的作用及其与MEK5轴的机制。研究表明MM细胞生存和增殖依赖RBM39,RBM39敲低抑制MM恶性生长;Indisulam(介导RBM39蛋白酶体降解的分子胶)在体外和体内均对MM有强效抑制作用。RBM39缺失导致剪接广泛改变,MEK5错剪接被证实可抑制MM恶性生长;全长MEK5维持MM细胞存活,而外显子缺失的异常MEK5异构体功能丧失并易被蛋白酶体降解。靶向RBM39或MEK5通过抑制p65协同增强硼替佐米对MM细胞的细胞毒性。
要点
- MM细胞生存和增殖依赖RBM39,RBM39敲低抑制MM恶性生长。
- Indisulam在体外和体内均对MM有强效抑制作用。
- 靶向RBM39或MEK5通过抑制p65协同增强硼替佐米对MM细胞的细胞毒性。
核心结论
- 本研究验证了RBM39在多发性骨髓瘤中的具体机制,为更广泛靶向和优化多发性骨髓瘤治疗策略提供了途径。
研究设计与样本
- 本研究为实验研究,探讨RBM39-MEK5轴在多发性骨髓瘤中的作用,并评估Indisulam及靶向RBM39或MEK5与硼替佐米联用的效果。
主要发现
- MM细胞生存和增殖依赖RBM39,RBM39敲低抑制MM恶性生长。
- Indisulam在体外和体内均对MM有强效抑制作用。
- RBM39缺失导致剪接广泛改变,MEK5错剪接被证实可抑制MM恶性生长。
- 全长MEK5维持MM细胞存活,而外显子缺失的异常MEK5异构体功能丧失并易被蛋白酶体降解。
- 靶向RBM39或MEK5通过抑制p65协同增强硼替佐米对MM细胞的细胞毒性。
关键数值与推荐
- 原文为实验研究,未报告指南或共识推荐条款。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aberrant alternative splicing is one of the hallmarks of cancer and is potentially based on upregulated expression-of-splicing factors in some types of cancer. Our previous study suggested that the splicing factor RBM39 is significantly upregulated in multiple myeloma (MM) and that its upregulation is positively associated with poor prognosis. Here, we further demonstrate that the survival and proliferation of MM cells rely on RBM39 and that RBM39 knockdown inhibits the malignant growth of MM. Indisulam, a "molecular glue" that mediates the proteasomal degradation of RBM39, has potent suppressive effects on MM both in vitro and in vivo. Deletion of RBM39 results in extensively altered splicing, with mis-splicing of MEK5 verified to inhibit the malignant growth of MM. Full-length MEK5 plays a vital role in maintaining MM cell survival, whereas aberrant MEK5 isoforms with exon loss exhibit loss of function and a propensity for proteasomal degradation. Targeting RBM39 or MEK5 synergistically increases the cytotoxicity of bortezomib in MM cells via the inhibition of p65. Our study validates the specific mechanism of RBM39 in MM, providing an approach for broader targeting and optimized therapeutic strategies for MM.
引用
- Liu J, Zhang Z, Xu W, et al. Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma. Blood Adv. 2025. PMID: 40048740. doi:10.1182/bloodadvances.2025015815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。